Incyte Corporation


Incyte Corporation (INCY) Shares Tumble on FDA Setback for Rheumatoid Arthritis Drug

Incyte Corporation (NASDAQ:INCY) investors are heading for the hills, after the drug maker, along with its partner Eli Lilly (NYSE:LLY), announced that the FDA issued …

This Top Analyst Sees Incyte Corporation (INCY) Shares Have Significant Upside Ahead

After Incyte Corporation (NASDAQ:INCY) announced positive clinical pipeline updates that had investors celebrating and shares soaring 9%, top analyst Eric Schmidt at Cowen …

Company Update (NASDAQ:INCY): Here’s Why Incyte Corporation Shares Are Rising 7% Today

Incyte Corporation (NASDAQ: INCY) and Merck (NYSE:MRK) announced the decision to advance the clinical development program investigating the combination of epacadostat, Incyte’s investigational oral …

Company Update (NASDAQ:INCY): Incyte Corporation and Merus NV Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies

Incyte Corporation (NASDAQ:INCY) and Merus NV (NASDAQ:MRUS) announced today that they have entered into a global, strategic collaboration agreement focused on the research, …

Company Update (NASDAQ:INCY): CHMP Recommends Approval of Incyte Corporation and Eli Lilly and Co’s Baricitinib for the Treatment of Active Rheumatoid Arthritis (RA)

Incyte Corporation (NASDAQ:INCY) and Eli Lilly and Co (NYSE:LLY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …

Stock Update (NASDAQ:INCY): Incyte Corporation Announces New Data Analyses of Two Phase 3 Trials in Rheumatoid Arthritis

Incyte Corporation (NASDAQ:INCY) and Eli Lilly and Company (NYSE:LLY) announced new data analyses of two phase 3 trials, RA-BUILD and RA-BEAM, showing that …

Stock Update (NASDAQ:INCY): Incyte Corporation Announces 3Q:16 Financial Results and Updates Key Clinical Programs

Incyte Corporation (NASDAQ:INCY) reports 2016 third-quarter financial results, including strong revenue growth driven by increased sales of Jakafi® (ruxolitinib) in the U.S.

Incyte Corporation (INCY) Epacadostat and Keytruda Could Be Best in Class Immuno-Oncology Combination: Top Analyst

At the European Society for Medical Oncology (ESMO) conference, Incyte Corporation (NASDAQ:INCY) presented updated data from its Phase I trial of epacadostat and …

Stock Update (NASDAQ:INCY): Incyte Corporation Presents Updated Data from Epacadostat at ESMO 2016

Incyte Corporation (NASDAQ:INCY) announced that updated data from the Phase I portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat, …